AERAS
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2003
- Initiating Organization: AERAS
- Initiator Type: Third-party organization
- Rare disease
- Disease focus:
Tuberculosis - Location: International
Abstract
Aeras is a fully integrated, global, nonprofit biotech with capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy, and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field Aeras has sponsored and conducted more than 25 clinical vaccine trials enrolling thousands of subjects and is a key partner in six active clinical development programs.
Mission
The Aeras mission is to develop new tuberculosis (TB) vaccines that are affordable and accessible to all who need them.
Structure & Governance
Board of Directors
Financing
Aeras R&D work is funded by key partners worldwide. Funding streams include grants from foundations and governments, investments from industry partners, and co-investments with other organizations, governments, and institutions.
Donor support drives innovation by strengthening and advancing the global pipeline of new TB vaccines, accelerating efforts toward ensuring their availability to all who need them.
Data Sharing
TB vaccine research and development is complex and costly. No one organization or institution can do it alone. Aeras works in partnership with individuals, research organizations, academic institutions, funders, policymakers, and others to advance TB vaccine science. Because of limited resources and the complex biology of TB, it is crucial for scientists in this field to share knowledge and work together.
Some of Aeras’ partners include the following:
Impact/Accomplishment
Aeras’ global partners include academic, public, and private institutions, which work together to build research capacity, install diagnostic and immunology lab infrastructure, and provide training and employment to world-class researchers.
South Africa is particularly poised as a key driver of TB vaccine innovation, because it has the highest incidence of the disease and is well-equipped with world-renowned researchers and infrastructure to conduct TB studies. Aeras’ in-country partners provide primary and follow-up care to communities involved in clinical trials. They educate the local communities and raise awareness about TB and vaccine trials.
Recently, the successful completion of the first large, Phase IIb trial in South Africa of nearly 3,000 infants showed that it is possible to conduct a trial of that scope and magnitude, even though the vaccine did not prove to be more efficacious than the widely used infant vaccine BCG.
Links/Social Media Feed
Homepage |
|
|
|
|
Sponsors & Partners
Albert Einstein College of Medicine |
Australian AID |
Bill & Melinda Gates foundation |
Chinese Center for Disease Control and Prevention |
Colorado State University |
Columbia University |
Cornell University |
Crucell |
Dartmouth University |
EDCTP |
U.S. Food and Drug Administration |
Fudan University |
GHIT Fund |
GlaxoSmithKline |
Harvard University |
Huazhong Agricultural University |
Imperial College London |
Infectious Disease Research Institute |
Institute Pasteur de Lille |
Johns Hopkins University |
London School of Hygiene & Tropical Medicine |
Maastricht University |
National Institute of Allergy and Infectious Diseases |
Okairos |
Oregon Health & Science University |
Pontificia Universidad Catolica de Chile |
Rijksoverheid |
Rutgers University |
Sanofi Pasteur |
South African Tuberculosis Vaccine Initiative (satvi) |
St. Louis University |
Statens Serum Institut |
StopTBPartnership |
Tuberculosis Vaccine Initiative |
Tulane University |
UKaid |
Universita Cattolica del Sacro Cuore |
University of Alberta |
University of British Columbia |
University of California, Berkeley |
University of California, Los Angeles |
University of Cape Town |
University of Maryland |
University of Oxford |
University of Pittsburgh |
University of Sydney |
University of Wales |
University of Wisconsin |
WellcomeTrust |
Wuhan University |